Explore the words cloud of the AutoCRAT project. It provides you a very rough idea of what is the project "AutoCRAT" about.
The following table provides information about the project.
NATIONAL UNIVERSITY OF IRELAND GALWAY
|Coordinator Country||Ireland [IE]|
|Total cost||7˙452˙770 €|
|EC max contribution||7˙452˙770 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2020-01-01 to 2023-12-31|
Take a look of project's partnership.
|1||NATIONAL UNIVERSITY OF IRELAND GALWAY||IE (Galway)||coordinator||1˙406˙250.00|
|2||FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.||DE (MUNCHEN)||participant||1˙683˙046.00|
|3||ACADEMISCH ZIEKENHUIS LEIDEN||NL (LEIDEN)||participant||1˙006˙181.00|
|4||UNIVERSITAETSKLINIKUM ESSEN||DE (ESSEN)||participant||760˙625.00|
|5||GOETEBORGS UNIVERSITET||SE (GOETEBORG)||participant||751˙048.00|
|6||UNIVERSITA DEGLI STUDI DI GENOVA||IT (GENOVA)||participant||750˙000.00|
|7||VALITACELL LTD||IE (DUBLIN 2)||participant||750˙000.00|
|8||PINTAIL LTD||IE (Blackrock)||participant||199˙993.00|
|9||PANAXEA BV||NL (AMSTERDAM)||participant||145˙625.00|
AutoCRAT will develop novel sustainable cell and cell-derived therapies for osteoarthritis (OA). Osteoarthritis, a major disease, results in degradation of cartilage. It is the most common chronic joint condition, currently affecting >40 million Europeans. As no effective treatments for OA are available, it imposes a huge burden on the individual patient and European health care systems. Adult mesenchymal stem/stromal cells (MSCs) show early, promising clinical treatment efficacy in OA. However, costs of MSC production prevents widespread use for patients. Using human induced pluripotent stem cells (hiPSC), AutoCRAT will generate articular chondrocytes (hiCHOs) for cartilage repair to prevent development of OA and hiMSCs to treat established disease as sustainable therapeutic cell sources for therapies. Discovery of the osteoarthritis-specific hiMSC secretome will enable further refinement of these next-generation therapies; this will be achieved by molecular analysis of: 1) hiMSCs treated with synovial fluid from OA patients 2) EVs derived from these therapeutically-activated cells to develop the therapeutic osteoarthritis secretome. To ensure sustainable supply of high quality, affordable products, AutoCRAT will also develop a manufacturing pipeline composed of automated, regulatory-compliant robotic systems for production of the developed hiCHOs and hiMSCs and cell-secreted extracellular vesicle (EVs). The manufacturing pipeline can be extended to many other major diseases. The AutoCRAT consortium is composed of leading European scientific teams in stem cell biology, OA, preclinical efficacy and safety demonstration, GMP- and GAMP-compliant manufacturing of MSCs, regulatory affairs and health economics analysis. All aspects of AutoCRAT discovery and translation innovations will be guided by the imperative to deliver economically viable and regulatory-compliant therapies to OA-patients, the European health care system at large, and benefits to the European economy.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AUTOCRAT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "AUTOCRAT" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More